News March 15, 2020
Positive results showed that Deep TMS may help chronic smokers quit – Data collected from first multicenter...
News February 10, 2020
Company to discontinue funding of study following insufficient demonstration of efficacy
News February 10, 2020
Lushi also to serve on Company’s audit committee
News February 10, 2020
Results demonstrate increased activity in attention-related brain networks treated with BrainsWay’s...
News December 2, 2019
Primary and secondary endpoint achieved with statistical significance. Company intends to meet with...
News November 25, 2019
Third quarter revenues were $5.9 million, up 38% over the same quarter in the prior year
News November 25, 2019
JERUSALEM and HACKENSACK, N.J., Nov. 25, 2019 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) and its...
News November 25, 2019
JERUSALEM, Nov. 25, 2019 – BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced...
News October 1, 2019
JERUSALEM, Oct. 01, 2019 – BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced...
News September 19, 2019
Company Intends to Appoint U.S.-Based CEO
News August 26, 2019
Company also announces changes to U.S. Management Team
News July 18, 2019
First head-to-head, randomized controlled trial of its kind comparing Deep TMS, TMS and medication in...
News June 27, 2019
First non-invasive device for OCD achieves 45% response rate among patients after one month follow up,...
News June 24, 2019
Since receiving De Novo clearance from FDA in August 2018, the Company has shipped OCD coils to 100 sites...
News June 13, 2019
JERUSALEM and HACKENSACK, N.J., June 13, 2019 – BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay”...
News May 22, 2019
More than 260 participants have been enrolled to the study
News March 5, 2019
Program supports physicians in successfully implementing OCD Deep TMS treatment, through in-depth clinical...